Celyad SA Company Profile (NASDAQ:CYAD)

About Celyad SA

Celyad SA logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYAD
  • CUSIP:
Key Metrics:
  • Previous Close: $22.35
  • 50 Day Moving Average: $21.20
  • 200 Day Moving Average: $20.76
  • 52-Week Range: $16.31 - $59.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.42
  • P/E Growth: 0.00
  • Market Cap: $208.15M
  • Outstanding Shares: 9,313,000
  • Beta: 1.63
Debt:
  • Current Ratio: 9.47%
Additional Links:
Companies Related to Celyad SA:

Analyst Ratings

Consensus Ratings for Celyad SA (NASDAQ:CYAD) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $95.00 (325.06% upside)

Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
DateFirmActionRatingPrice TargetDetails
6/7/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00View Rating Details
12/1/2015Maxim GroupReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Celyad SA (NASDAQ:CYAD)
Current Year EPS Consensus Estimate: $-5.02 EPS
Next Year EPS Consensus Estimate: $-4.12 EPS

Dividends

Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Celyad SA (NASDAQ:CYAD)
DateHeadline
News IconCelyad SA (CYAD) – Latest Broker Consensus - NewsDen (NASDAQ:CYAD)
newsden.net - February 25 at 9:25 PM
News IconCelyad SA (ADR) (NASDAQ:CYAD) Price Target & Session Check - Rockville Register (NASDAQ:CYAD)
rockvilleregister.com - February 24 at 5:09 PM
News IconCelyad SA (CYAD) Given $35.67 Average Target Price by the Analysts - Petro Global News 24 (NASDAQ:CYAD)
petroglobalnews24.com - February 24 at 5:09 PM
News IconAnalysts Take the Wheel on Celyad SA (ADR) (NASDAQ:CYAD) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:CYAD)
aikenadvocate.com - February 22 at 5:10 AM
us.rd.yahoo.com logoCelyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial (NASDAQ:CYAD)
us.rd.yahoo.com - February 16 at 1:47 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Celyad SA (ADR) (NASDAQ:CYAD) - Aiken Advocate (NASDAQ:CYAD)
aikenadvocate.com - February 1 at 3:18 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Celyad SA (ADR) (NASDAQ:CYAD)? - Wall Street Beacon (NASDAQ:CYAD)
wsbeacon.com - February 1 at 3:18 AM
News IconEarnings in Full Force, Analysts Take Aim at Celyad SA (ADR) (NASDAQ:CYAD) - Wall Street Beacon (NASDAQ:CYAD)
wsbeacon.com - January 26 at 5:49 PM
News IconWhat is the Street Saying About Celyad SA (ADR) (NASDAQ:CYAD)? - Aiken Advocate (NASDAQ:CYAD)
aikenadvocate.com - January 26 at 5:49 PM
News IconBrokers Release Average Price Target Of 61.00 On Celyad SA (CYAD) - UK Market News (NASDAQ:CYAD)
www.ukmarketnews.co.uk - January 26 at 5:49 PM
News IconWill The Needle Move For Celyad SA (ADR) (NASDAQ:CYAD) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CYAD)
wsbeacon.com - January 17 at 5:31 PM
streetinsider.com logoCelyad SA (CYAD) Reports Activation of Second Site in Belgium for ... - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - January 13 at 3:04 AM
streetinsider.com logoCelyad SA (CYAD) Reports Activation of Second Site in Belgium for THINK Trial (NASDAQ:CYAD)
www.streetinsider.com - January 12 at 10:02 PM
finance.yahoo.com logoCelyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium (NASDAQ:CYAD)
finance.yahoo.com - January 11 at 5:04 PM
investing.com logoCelyad: Colorectal Patient In THINK Study (NASDAQ:CYAD)
www.investing.com - January 10 at 2:29 AM
News IconCelyad Announces Registration of the first patient in the Belgian THINK trial (Celyad SA) (NASDAQ:CYAD)
www.newsoneplace.com - January 5 at 3:42 AM
publicnow.com logoCelyad Announces Registration of the first patient in the Belgian THINK trial (NASDAQ:CYAD)
us.rd.yahoo.com - January 5 at 3:42 AM
News IconCelyad SA (CYAD) Under Analyst Spotlight - UK Market News (NASDAQ:CYAD)
www.ukmarketnews.co.uk - December 31 at 3:02 AM
News IconThis Weeks Target Prices For Celyad SA (CYAD) - NewsDen (NASDAQ:CYAD)
newsden.net - December 15 at 5:03 PM
finance.yahoo.com logoEdison Issues ADR Update on Celyad (CYAD) (NASDAQ:CYAD)
finance.yahoo.com - December 13 at 9:26 AM
News IconCelyad SA (CYAD) Valuation According To Analysts - UK Market News (NASDAQ:CYAD)
www.ukmarketnews.co.uk - December 9 at 4:55 PM
us.rd.yahoo.com logoCELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting (NASDAQ:CYAD)
us.rd.yahoo.com - December 7 at 9:37 AM
us.rd.yahoo.com logo3:54 am Celyad SA presents new data from its CAR-T NKR-2 Phase I Trial; demonstrates strong safety signals, including no cases of cytokine release syndrome (NASDAQ:CYAD)
us.rd.yahoo.com - December 7 at 9:37 AM
globenewswire.com logoCELYAD S.A.: Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting - GlobeNewswire (press release) (NASDAQ:CYAD)
globenewswire.com - December 6 at 11:40 AM
investing.com logoCelyad: Unexpected CAR Clinical Benefit - Investing.com (NASDAQ:CYAD)
www.investing.com - November 30 at 8:00 AM
investing.com logoCelyad: Unexpected CAR Clinical Benefit (NASDAQ:CYAD)
www.investing.com - November 29 at 5:50 PM
live-pr.com logo"Celyad SA (CYAD) - Medical Equipment - Deals and Alliances Profile" is now available at Fast Market Research (NASDAQ:CYAD)
www.live-pr.com - November 25 at 9:46 AM
streetinsider.com logoCelyad SA (CYAD) Receives Approval in Belgium to Commence NKR-2 CAR-T Clinical Trial - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - November 21 at 9:29 AM
publicnow.com logoCelyad announces the approval to initiate its NKR-2 CAR-T Clinical Trial in Belgium (NASDAQ:CYAD)
www.publicnow.com - November 21 at 9:29 AM
News IconCelyad SA CYAD Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:CYAD)
www.bioportfolio.com - November 20 at 8:39 AM
publicnow.com logoCelyad announces third quarter 2016 business update (NASDAQ:CYAD)
www.publicnow.com - November 18 at 1:38 PM
News IconEarnings According to Analysts for Celyad SA (ADR) (NASDAQ:CYAD)? - CSZ News (NASDAQ:CYAD)
cincysportszone.com - November 16 at 4:36 PM
News IconTrading Radar: Checking Technicals for Celyad Sa (CYAD) - StockTalk Daily (NASDAQ:CYAD)
stocktalkdaily.com - November 15 at 4:53 PM
News IconAnalysts Set $49.00 Target Price for Celyad SA (CYAD) - Digital Cameras Planet Blog (blog) (NASDAQ:CYAD)
digital-cameras-planet.com - November 11 at 9:48 PM
streetinsider.com logoCelyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016 (NASDAQ:CYAD)
www.streetinsider.com - November 7 at 11:14 PM
streetinsider.com logoCelyad SA (CYAD) Announces Presentation of Encouraging NKR-2 Phase I Data at ASH 2016 - StreetInsider.com (NASDAQ:CYAD)
www.streetinsider.com - November 7 at 4:18 PM
publicnow.com logoCelyad’s NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016 (NASDAQ:CYAD)
www.publicnow.com - November 7 at 6:50 AM
finance.yahoo.com logoCelyad's NKR-2 Phase I safety trial delivers encouraging results to be presented at ASH 2016 (NASDAQ:CYAD)
finance.yahoo.com - November 7 at 6:50 AM
finance.yahoo.com logo3:08 am Celyad SA to present encouraging data in NKR-2 Phase I Safety Trial at ASH (NASDAQ:CYAD)
finance.yahoo.com - November 7 at 6:50 AM
News IconBroker Changes For Celyad SA (NASDAQ:CYAD) - NewsDen (NASDAQ:CYAD)
newsden.net - November 6 at 9:19 AM
News IconCelyad SA (NASDAQ:CYAD) Updated Broker Ratings - NewsDen (NASDAQ:CYAD)
newsden.net - November 3 at 10:03 PM
publicnow.com logoCelyad responds to misleading statements on its patent relating to allogeneic human primary T-Cells that are engineered to be TCR-deficient and express a CAR (NASDAQ:CYAD)
www.publicnow.com - November 3 at 7:59 AM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Celyad SA (ADR) (NASDAQ:CYAD) Shares - CSZ News (NASDAQ:CYAD)
cincysportszone.com - November 1 at 9:56 PM
News IconAnalysts Take the Wheel on Celyad SA (ADR) (NASDAQ:CYAD) Shares and Where They Might Be Headed - CSZ News (NASDAQ:CYAD)
cincysportszone.com - October 26 at 4:34 PM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Celyad SA (ADR) (NASDAQ:CYAD) - CSZ News (NASDAQ:CYAD)
cincysportszone.com - October 19 at 9:28 AM
News IconCelyad SA (CYAD) Updated Analyst Coverage - NewsDen (NASDAQ:CYAD)
newsden.net - October 19 at 9:28 AM
News IconCelyad SA (CYAD) Updated Broker Ratings - NewsDen (NASDAQ:CYAD)
newsden.net - October 13 at 4:30 PM
News IconCelyad SA (CYAD) Analyst Review - NewsDen (NASDAQ:CYAD)
newsden.net - October 6 at 4:29 PM
News IconCurrent Price Targets For Celyad SA (CYAD) - NewsDen (NASDAQ:CYAD)
newsden.net - September 28 at 9:25 AM
investorplace.com logoBiggest Movers in Manufacturing Stocks Now - IPCI ARDM GLMD PTI - Investorplace.com (NASDAQ:CYAD)
investorplace.com - September 24 at 4:21 PM

Social

What is Celyad SA's stock symbol?

Celyad SA trades on the NASDAQ under the ticker symbol "CYAD."

Where is Celyad SA's stock going? Where will Celyad SA's stock price be in 2017?

1 equities research analysts have issued twelve-month price targets for Celyad SA's shares. Their forecasts range from $95.00 to $95.00. On average, they anticipate Celyad SA's share price to reach $95.00 in the next year.

How do I buy Celyad SA stock?

Shares of Celyad SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Celyad SA stock cost?

One share of Celyad SA stock can currently be purchased for approximately $22.35.

Celyad SA (NASDAQ:CYAD) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Celyad SA (NASDAQ:CYAD)

Earnings History Chart

Earnings by Quarter for Celyad SA (NASDAQ:CYAD)

Dividend History Chart

Dividend Payments by Quarter for Celyad SA (NASDAQ:CYAD)

Last Updated on 2/25/2017 by MarketBeat.com Staff